Products
Latest news
-
AbSorber receives part of €2.6M EU grant in collaboration with EUROSTAM
-
Olerup introduces new SBT Resolver DRB1 seqencing assay
-
University of Heidelberg becomes a reference laboratory for XM-ONE®
-
Rush University Medical Center and AbSorber Enter Into a Collaborative Validation Study
Suppliers
XM-ONE®
XM-ONE® provides additional information compared to the currently used lymphocyte crossmatch tests and therefore improves the basis for risk assessment prior to transplantation.
| Product name | No. Of tests | List price |
|---|---|---|
| XM-ONE® Transplantation crossmatch | 4 | Inquire |
XM-ONE® Proficiency Testing Program
Accuracy and standardization of crossmatch results between different centers are essential in organ transplantation. The XM-ONE® proficiency testing (PT) program serves as an important function in accomplishing this goal. The PT program for XM-ONE® is approved by The American Society for Histocompatibility and Immunogenetics (ASHI).
The study showed that the XM-ONE® test can detect an antibody population not possible to detect with lymphocyte crossmatch tests that is strongly associated with rejection episodes and reduced kidney function after transplantation. Thus the XM-ONE® test can identify patients at risk of antibody-mediated rejections.
